Fezolinetant

Generic Name
Fezolinetant
Brand Names
Veozah, Veoza
Drug Type
Small Molecule
Chemical Formula
C16H15FN6OS
CAS Number
1629229-37-3
Unique Ingredient Identifier
83VNE45KXX
Background

Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are the most common symptoms, if not the cardinal symptoms, in women. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues. Although mostly considered a nuisance, vasomotor symptoms could potent...

Indication

Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Associated Conditions
Moderate to Severe Vasomotor Symptoms
Associated Therapies
-
Clinical Trials
Related News

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

First Posted Date
2024-09-27
Last Posted Date
2024-11-20
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
36
Registration Number
NCT06617455
Locations
🇺🇸

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

First Posted Date
2024-06-04
Last Posted Date
2024-10-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
540
Registration Number
NCT06440967
Locations
🇨🇦

Site CA15002, Montreal, Quebec, Canada

🇨🇦

Site CA15001, Quebec City, Quebec, Canada

🇨🇦

Site CA15003, Sherbrooke, Quebec, Canada

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

Phase 3
Recruiting
Conditions
Hot Flashes
Interventions
Drug: Fezolinetant
Drug: Placebo
First Posted Date
2024-01-16
Last Posted Date
2024-12-09
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
390
Registration Number
NCT06206408
Locations
🇯🇵

MEITETSU Hospital, Nagoya-shi, Aichi, Japan

🇯🇵

Toyota Kosei Hospital, Toyota-shi, Aichi, Japan

🇯🇵

Shimizu Ladies Clinic, Sakai-shi, Osaka, Japan

and more 61 locations

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

Phase 3
Recruiting
Conditions
Hot Flashes
Interventions
Drug: Placebo
Drug: Fezolinetant
First Posted Date
2024-01-16
Last Posted Date
2024-11-25
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
260
Registration Number
NCT06206421
Locations
🇯🇵

M's Ladies Clinic, Sapporo-shi, Hokkaido, Japan

🇯🇵

Motomachi Ladies Clinic, Yokohama-shi, Kanagawa, Japan

🇯🇵

Tennoji Chihiro Women's Clinic, Osaka-shi, Osaka, Japan

and more 21 locations

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

First Posted Date
2023-09-22
Last Posted Date
2024-12-17
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
1000
Registration Number
NCT06049797
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

SUNY Downstate Health Sciences University, Brooklyn, New York, United States

🇺🇸

Mohawk Valley Health System - Womens Health Center, Utica, New York, United States

and more 54 locations

Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

Phase 2
Completed
Conditions
Hot Flashes
Interventions
Drug: Placebo
Drug: Fezolinetant
First Posted Date
2022-06-15
Last Posted Date
2024-11-27
Lead Sponsor
Ogeda S.A.
Target Recruit Count
87
Registration Number
NCT05419908
Locations
🇧🇪

Site BE32009, Tienen, Belgium

🇧🇪

Site BE32001, Gent, Belgium

🇧🇪

Site BE32004, Brussels, Belgium

and more 5 locations

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Phase 3
Completed
Conditions
Vasomotor Symptoms
Interventions
Drug: placebo
Drug: fezolinetant
First Posted Date
2021-09-05
Last Posted Date
2024-10-26
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
453
Registration Number
NCT05033886
Locations
🇫🇮

Site FI35803, Oulu, Finland

🇵🇱

Site PL48013, Bydgoszcz, Poland

🇳🇴

Site NO47001, Hamar, Norway

and more 66 locations

A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Phase 2
Completed
Conditions
Hot Flashes
Interventions
Drug: Fezolinetant
Drug: Placebo
First Posted Date
2021-09-05
Last Posted Date
2024-10-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
147
Registration Number
NCT05034042
Locations
🇯🇵

Sapporo Medical Center, NTT East Corporation, Sapporo-shi, Hokkaido, Japan

🇯🇵

Yoshinaga Women's Clinic, Kagoshima-shi, Kagoshima, Japan

🇯🇵

Tonan Hospital, Sapporo-shi, Hokkaido, Japan

and more 37 locations

A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: fezolinetant
First Posted Date
2021-03-11
Last Posted Date
2024-10-26
Lead Sponsor
Astellas Pharma China, Inc.
Target Recruit Count
16
Registration Number
NCT04793204
Locations
🇨🇳

Site CN86001, Bei'jing, China

A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Fezolinetant
First Posted Date
2020-11-23
Last Posted Date
2024-10-18
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
16
Registration Number
NCT04641260
Locations
🇺🇸

Parexel, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy